CRDF
Cardiff Oncology Inc

18,848
Loading...
Loading...
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
33

Frequently Asked Questions

What is Market Cap of Cardiff Oncology Inc?
What is the 52-week high for Cardiff Oncology Inc?
What is the 52-week low for Cardiff Oncology Inc?
What is Cardiff Oncology Inc stock price today?
What was Cardiff Oncology Inc stock price yesterday?
What is the PE ratio of Cardiff Oncology Inc?
What is the Price-to-Book ratio of Cardiff Oncology Inc?
What is the 50-day moving average of Cardiff Oncology Inc?
How many employess does Cardiff Oncology Inc has?

Latest CRDF News

View

Advertisement. Remove ads.

Advertisement. Remove ads.